Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Post-Trial Drug Access
Drugs
Locations
Clinical Specialty
241-260 of 847 trials

Severe Hemophilia A: Continued Access to Efanesoctocog Alfa

We are providing ongoing treatment access for patients with severe hemophilia A who completed a previous trial with efanesoctocog alfa. The study aims to gather more information on its safety and effectiveness in preventing and treating bleeding episodes.

Haemophilia AConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteHematologyInternal Medicine

Atopic Dermatitis: Long-Term Study of Amlitelimab

We are evaluating the long-term safety and effectiveness of amlitelimab for individuals with moderate to severe atopic dermatitis who have participated in earlier studies. This research aims to better understand how the treatment works over time.

Atopic Dermatitis>2 yearsEfficacy phase (II)Confirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteAllergologyDermatology

Lennox-Gastaut Syndrome: Carisbamate Treatment Study

We are investigating whether carisbamate can help reduce drop seizures in children and adults with Lennox-Gastaut Syndrome. This study will also look at the safety and tolerability of the medication.

Lennox-Gastaut Syndrome3-6 monthsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Niraparib: Long-Term Safety Study for Cancer Patients

We are evaluating the long-term safety and tolerability of niraparib for patients who have previously completed a study and are deemed to benefit from continued treatment. This study helps us understand how well the medication can be tolerated over time.

Advanced Ovarian, Breast, or Prostate CancerEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteOncology

Giant Cell Arteritis: Etanercept vs. Methotrexate

We are comparing two treatments, etanercept and methotrexate, to see which is more effective for patients with giant cell arteritis. The goal is to find out which treatment helps achieve remission and prevents complications better.

Giant Cell ArteritisEfficacy phase (II)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesInfectious DiseasesRheumatology

Ulcerative Colitis: Dual Therapy Study

We are comparing single and combination therapies for patients with ulcerative colitis who didn't respond to previous treatment. The goal is to see which option may help achieve better remission and quality of life.

Ulcerative Colitis>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Rheumatoid Arthritis: Rituximab Tapering Strategies

We are studying different ways to reduce rituximab doses in patients with rheumatoid arthritis. The goal is to find the best method to lower disease impact and activity.

Rheumatoid Arthritis>2 yearsMonitoring phase (IV)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementInternal MedicineRheumatology

Non-Hodgkin Lymphoma: BMS-986458 Treatment Study

We are testing a new drug, BMS-986458, for people with relapsed or refractory non-Hodgkin lymphoma. The study aims to understand its safety and how it works alone and with other treatments.

Non-Hodgkin Lymphoma>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Multiple Myeloma: Etentamig Treatment Study

We are studying a new medication, Etentamig, for adults with relapsed or refractory multiple myeloma who have already received multiple treatments. The goal is to see if it is more effective and safe compared to standard therapies.

Relapsed or Refractory Multiple MyelomaConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyOncology

Prostate Cancer: 12-Month Treatment Study

We are studying whether stopping a treatment for prostate cancer after 12 months is as effective as continuing it. This may help reduce side effects and costs for patients with low-volume metastatic castration-sensitive prostate cancer.

Low-Volume Metastatic Castration-Sensitive Prostate Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncologyUrology

HER2-Low Breast Cancer: Trastuzumab-Deruxtecan Study

We are studying a new treatment for patients with HER2-low breast cancer and brain metastases to see if it helps shrink tumors and improve quality of life. This trial will also look at safety and how well patients tolerate the treatment.

HER2-Low Breast Cancer with Brain Metastases1-2 yearsEfficacy phase (II)≤5 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesNeurologyOncology

Crohn's Disease: TAK-279 Oral Medication

We are studying a new oral treatment for people with moderately to severely active Crohn's disease. The trial aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Metastatic Breast Cancer: [177Lu]Lu-NeoB with Capecitabine

We are studying a new treatment combining [177Lu]Lu-NeoB and capecitabine for adults with specific metastatic breast cancer. The goal is to find the best doses and evaluate how well it works after other treatments have failed.

Metastatic Breast Cancer6-12 monthsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOncology

Advanced Solid Tumors: AZD3470 Study

We are testing a new drug, AZD3470, for patients with advanced solid tumors lacking the MTAP gene. The study aims to evaluate its safety and effectiveness, both alone and with other cancer treatments.

Advanced Metastatic Solid Tumors (MTAP Deficient)Safety phase (I)11-15 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Spinal Muscular Atrophy: RO7204239 with Risdiplam

We are studying the safety and effectiveness of a new treatment combining RO7204239 with risdiplam for individuals with spinal muscular atrophy. This trial will help us understand how well this combination works compared to a placebo.

Spinal Muscular Atrophy (SMA)1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessPartially RemoteInternal MedicineNeurology

Ulcerative Colitis: TAK-279 Oral Medication

We are testing the effectiveness of TAK-279 for people with moderately to severely active ulcerative colitis. The study aims to see if it helps achieve remission and improves symptoms compared to a placebo.

Ulcerative Colitis1-2 yearsEfficacy phase (II)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementGastroenterologyInternal Medicine

Lung Cancer: Selpercatinib Study

We are testing a new treatment called selpercatinib for patients with RET fusion-positive non-small cell lung cancer. The goal is to see if it improves outcomes compared to a placebo.

RET Fusion-Positive Non-Small Cell Lung Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteOncologyPulmonology

Pulmonary Hypertension: Long-term Safety Study

We are evaluating the long-term safety of treatments for pulmonary hypertension in participants who have previously received these interventions. This study aims to ensure ongoing safety for those already involved in related research.

Pulmonary HypertensionConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemotePulmonology

Adrenomyeloneuropathy: Dimethyl Fumarate Study

We are investigating whether dimethyl fumarate can improve symptoms in patients with adrenomyeloneuropathy compared to a placebo. The trial also looks at the safety of this medication.

Adrenomyeloneuropathy>2 yearsEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Neurodegenerative Disease: Continued Access to Latozinemab

We are offering ongoing access to the medication latozinemab for individuals with neurodegenerative diseases who have participated in earlier studies. The trial will monitor safety and any clinical benefits from continued treatment.

Neurodegenerative DisordersConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology